Scientists pinpoint ideal painkiller dose for diabetic foot operations

NCT ID NCT04981067

Ongoing Symptom relief Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to find the smallest effective dose of the numbing drug ropivacaine for blocking leg nerves during diabetic foot surgery. Researchers will test different concentrations in 45 adults to see which dose works best for 90% of patients. The goal is to provide effective pain relief while using the lowest possible amount of medicine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ropivacaine
What this could lead to: If successful, this could help doctors use the right amount of numbing medicine for diabetic foot surgery, reducing pain and risks.
What could go wrong: This is a small, early-phase study with only 45 people. The results may not apply to everyone, and the best dose might still cause side effects or fail to numb properly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC FOOT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Diabetic Foot diabetic neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC FOOT DIABETIC NEUROPATHIES

Contacts and locations

Locations

Seoul National University Hospital

Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.